false. my comment was that they cannot afford to fund a phase III trial. That is a true statement.
someone else running a phase iii trial on their behalf in an indication that most are not confident in succeeding is not enough to raise the SP unless results surprise.
they themselves need to be able to fund a trial in kidney disease for this to be worth something.
Ann: Half Year Report and Update, page-78
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.005(1.49%) |
Mkt cap ! $181.3M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $1.121M | 3.386M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 907553 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 195382 | 3 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
33.0¢ |
Change
-0.005 ( 1.49 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 34.0¢ | 32.5¢ | 1712129 | ||
| Last updated 15.54pm 10/05/2024 ? | |||||
| DXB (ASX) Chart |